IN BRIEF: PureTech Health promotes interim CEO Robert Lyne to CEO

Related news

PureTech Health PLC - Boston, Massachusetts-based biotech and pharmaceutical firm - Promotes interim Chief Executive Officer Robert Lyne to CEO on a permanent basis from Thursday. Lyne has served as interim CEO since July, having joined the company in January 2024 as chief portfolio officer. He has overseen progress across PureTech’s programmes and advancing strategic and operational priorities. Lyne was previously CEO of Arix Bioscience PLC.

Current stock price: 121.96 pence, up 1.1% on Thursday morning in London

12-month change: down 26%

Copyright 2025 Alliance News Ltd. All Rights Reserved.

Directors

Ways to help you invest your money

Our investment accounts

Put your money to work with our range of investment accounts. Choose from ISAs, pensions, and more.

Need some investment ideas?

Let us give you a hand choosing investments. From managed funds to favourite picks, we’re here to help.

Read our expert tips and insights

Our investment experts share their knowledge on how to keep your money working hard across the markets.